ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
120.445,91
0,15%
S&P 500
5.473,17
-0,25%
US Dollar vs BRL
5,4539
0,55%
Bitcoin
64.963,56
-0,01%
Brent Oil
85,005
0,37%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Ascendis Pharma AS (ASND)

  7. Ascendis Pharma AS (ASND) Notícias

ASND

Ascendis Pharma AS (ASND)

Ascendis Pharma AS
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ASND
DataHoraFonteTítuloCódigoCompanhia
12/06/202417:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
04/06/202417:01GlobeNewswire Inc.Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ASNDAscendis Pharma AS
03/06/202417:01GlobeNewswire Inc.Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024NASDAQ:ASNDAscendis Pharma AS
30/05/202409:30GlobeNewswire Inc.Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024NASDAQ:ASNDAscendis Pharma AS
29/05/202417:08Edgar (US Regulatory)Form SD - Specialized disclosure reportNASDAQ:ASNDAscendis Pharma AS
14/05/202415:31GlobeNewswire Inc.Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
13/05/202409:30GlobeNewswire Inc.Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway TrialNASDAQ:ASNDAscendis Pharma AS
09/05/202409:30GlobeNewswire Inc.Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024NASDAQ:ASNDAscendis Pharma AS
02/05/202417:01GlobeNewswire Inc.Ascendis Pharma Reports First Quarter 2024 Financial ResultsNASDAQ:ASNDAscendis Pharma AS
25/04/202417:46GlobeNewswire Inc.Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024NASDAQ:ASNDAscendis Pharma AS
24/04/202409:30GlobeNewswire Inc.United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
07/03/202413:31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
04/03/202410:30GlobeNewswire Inc.Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:ASNDAscendis Pharma AS
14/02/202411:17Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ASNDAscendis Pharma AS
07/02/202418:15Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:ASNDAscendis Pharma AS
07/02/202418:01GlobeNewswire Inc.Ascendis Pharma Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:ASNDAscendis Pharma AS
07/02/202410:30GlobeNewswire Inc.Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ASNDAscendis Pharma AS
31/01/202418:15GlobeNewswire Inc.Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024NASDAQ:ASNDAscendis Pharma AS
31/01/202418:01GlobeNewswire Inc.Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
29/01/202410:30GlobeNewswire Inc.New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External InvestorsNASDAQ:ASNDAscendis Pharma AS
08/01/202410:20GlobeNewswire Inc.Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries NASDAQ:ASNDAscendis Pharma AS
07/01/202419:45GlobeNewswire Inc.Ascendis Pharma Introduces Vision 2030NASDAQ:ASNDAscendis Pharma AS
07/01/202416:00PR Newswire (US)Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countriesNASDAQ:ASNDAscendis Pharma AS
28/12/202318:15GlobeNewswire Inc.Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ASNDAscendis Pharma AS
20/12/202310:30GlobeNewswire Inc.Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/weekNASDAQ:ASNDAscendis Pharma AS
19/12/202310:30GlobeNewswire Inc.TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone DeficiencyNASDAQ:ASNDAscendis Pharma AS
11/12/202310:30GlobeNewswire Inc.FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
29/11/202306:30GlobeNewswire Inc.Ascendis Pharma Announces Strategic Partnership with Teijin Limited in JapanNASDAQ:ASNDAscendis Pharma AS
20/11/202310:00GlobeNewswire Inc.Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
15/11/202310:00GlobeNewswire Inc.Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDANASDAQ:ASNDAscendis Pharma AS
 Apresentando as notícias mais relevantes sobre:NASDAQ:ASND

Seu Histórico Recente

USOTC
EXSPF
Expert ai (PK)
BOV
P1EA34Q
Healthpeak OP
BIT
P1YTD5
NLBNPIT1YTD5 20351221 2....
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados